ReNeuron Group Plc has taken a decision to out-license a clinical-stage cell therapy programme for retinitis pigmentosa (RP), an eye disease in which the retina is damaged, and focus instead on developing its exosome technology. The decision was announced to the London Stock Exchange on 18 January.
Belgium-based UCB SA is to acquire a US developer of drugs for rare diseases in a move that will both expand its existing epilepsy franchise and give it access to gene therapy technology. The proposed acquisition of Zogenix Inc of Emeryville, California is valued at approximately $1.9 billion (€1.7 billion) and has been approved by the boards of directors of both companies.
A Phase 2 trial of a small molecule drug for the treatment of sudden sensorineural hearing loss, or sudden deafness, failed to meet its primary efficacy endpoint, the developer Sensorion SA, announced on 17 January. The drug, SENS-401, was safe and well-tolerated but did not show a significant improvement in pure tone audiometry, a test used to measure hearing sensitivity. In the trial, it was compared with a placebo and administered to patients over a period of four weeks. The trial, AUDIBLE-S, enrolled 115 patients.
Evotec SE is to collaborate with Eli Lilly and Co to discover up to five potential therapeutics for diabetes and chronic kidney diseases, leveraging its experience in metabolic disease discovery to investigate new approaches. Evotec has already worked with Novo Nordisk A/S on possible treatments for kidney diseases and has access to a kidney disease patient database to identify and validate possible drug targets. In the field of diabetes, it has a proprietary beta cell replacement therapy in preclinical development.
GlaxoSmithKline Plc has confirmed media reports that it was approached three times by Unilever Plc to sell its joint venture consumer healthcare unit, but rejected the overtures. The most recent offer, made on 20 December 2021 was for £50 billion which would have comprised £41.7 billion in cash and £8.3 billion in Unilever shares. “GSK rejected all three proposals made on the basis that they fundamentally undervalued the consumer healthcare business and its future prospects,” the company said in a statement on 15 January 2022.
AstraZeneca Plc has agreed to pay $75 million initially, and up to an additional $1.5 billion in option fees and milestone payments, for rights to up to three small molecule therapeutics for cancer. The partner is Scorpion Therapeutics Inc of Boston, US, which has an integrated platform for drug discovery drawing on chemical proteomics, structure-based drug design and machine learning.
Sanofi SA has signed a new licensing agreement with Exscientia Plc, a UK drug discovery firm, to tap its expertise in artificial intelligence for the development of up to 15 small molecule drug candidates in the fields of oncology and immunology.
The two companies have been working together since 2016 and in 2019, Sanofi in-licensed a bispecific small molecule directed against two targets in inflammation and immunology.
UK-based Crescendo Biologics Ltd has entered into a multi-target discovery collaboration with BioNTech SE of Germany to develop immunotherapies for cancer and other diseases, its sixth industrial partnership since the company’s founding in 2007. The two companies will look at developing potential messenger RNA (mRNA)-based antibody therapeutics as well as engineered cell therapies.
AstraZeneca Plc has negotiated rights to an early clinical stage therapeutic designed to remove amyloid fibril deposits in the heart. The agreement, with Neurimmune AG of Switzerland, relates to NI006, a monoclonal antibody in Phase 1b for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), a systemic condition that can lead to progressive heart failure.
The disease is caused by aging or genetic mutations resulting in a misfolding of the transthyretin protein and an accumulation as amyloid fibrils in the cardiac myocardium.
Novartis is to work with Alnylam Pharmaceuticals Inc on a potential treatment to restore liver function in patients with end-stage liver disease. The three-year research agreement will test potential small interfering RNA (siRNA) therapeutics against a target discovered by Novartis in order to promote the regrowth of functional liver cells. The goal is to provide an alternative to transplantation for patients with liver failure, the Swiss company announced on 9 January.